The first participant in the Phase III clinical trial of the innovative drug “Angaliduv” by Zhongsheng Pharmaceutical has been successfully enrolled
November 24, 2025
Source: drugdu
99
On November 23rd, Shengli Pharmaceutical (002317) issued a notice stating that its wholly-owned subsidiary, Shengli Ruichuang, has completed the enrollment and administration of the first participant in the Phase III clinical trial of its first-class innovative drug, Angaliduvir Granules, for the treatment of children aged 2 to 11 with uncomplicated influenza A. Angaliduvir Granules were developed to facilitate medication use for children and those with swallowing difficulties. The results of the Phase II clinical trial showed positive efficacy and good safety.
The Phase III clinical trial of oneladivir granules has been progressing smoothly under the guidance of Beijing Children's Hospital, affiliated to Capital Medical University. The announcement states that the completion of this clinical trial will not have a significant impact on the company's short-term financial situation and operating performance.
In the first three quarters of 2025, Sinos Pharmaceutical achieved revenue of 1.889 billion yuan and net profit attributable to the parent company of 251 million yuan.
https://finance.eastmoney.com/a/202511233572153297.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
